The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1739
ISSUE 1739
October 13, 2025
Issue 1739
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Semaglutide (Wegovy) for MASH
October 13, 2025 (Issue: 1739)
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist semaglutide (Wegovy) has received
accelerated approval from the FDA for treatment
of noncirrhotic metabolic dysfunction-associated
steatohepatitis (MASH; previously known...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.